Home Diagnostics, which develops and markets blood glucose monitoring systems and disposable test strips for diabetics, priced its offering of 6.6 million shares at $12, a 20% discount to the midpoint of its proposed $14 to $16 range, on Wednesday night. Approximately half of the shares were offered by the company, with the remainder coming from insiders. JP Morgan was the lead underwriter on the deal. The stock is expected to begin trading on Thursday under the ticker HDIX on the NASDAQ.
